• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Fuse Medical wins FDA 510(k) clearance for Sterizo knee system

Fuse Medical wins FDA 510(k) clearance for Sterizo knee system

August 26, 2021 By Sean Whooley

Fuse MedicalFuse Medical announced today that it received FDA 510(k) clearance for its tibial revision knee system and stabilized tibial insert.

Richardson, Texas-based Fuse Medical’s tibial revision knee system and the PS Plus posterior stabilized tibial insert represent the latest additions to the company’s Sterizo total knee system.

According to a news release, the Sterizo tibial revision knee system offers surgeons a stemmed option in a primary total knee arthroplasty for patients with higher body mass index (BMI) or requiring additional stability, along with tibial augments to address anatomical defects.

The platform constitutes the basis of the Sterizo total revision knee system, which Fuse currently has under development with an eye on an initial launch in late 2022.

Fuse’s Sterizo PS Plus posterior stabilized tibial insert provides increased varus/valgus constraint and limits internal/external rotation compared to the standard Sterizo posterior stabilized tibial insert to accommodate patients requiring more constraint.

The company said the product line extension will complement the available offerings with the Sterizo primary total knee system, which include cruciate retained, ultra congruent/anterior stabilized and posterior stabilized options.

“With our Sterizo tibial revision knee system cleared for use in primary applications, we can now offer the additional options surgeons may need to meet specific patient anatomy requirements,” Fuse CEO Christopher C. Reeg said in the release. “The expansion of offerings for our Sterizo total knee system demonstrates our continued commitment to develop and expand our portfolio of Fuse manufactured medical device products.

“Adding these new options to the already robust Sterizo platform allows us to better target new distribution and sales channels. These new products, along with our future product development pipeline, will also assist in attracting experienced sales professionals in our industry. Our priority at Fuse remains to provide innovative solutions for today’s clinical challenges and assist with improving surgical outcomes.”

Filed Under: 510(k), Featured, Food & Drug Administration (FDA), Orthopedics, Regulatory/Compliance Tagged With: FDA, fusemedical

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy